Edwards Lifesciences Corp (EW)vsNuwellis Inc (NUWE)
EW
Edwards Lifesciences Corp
$84.37
-2.77%
HEALTHCARE · Cap: $49.99B
NUWE
Nuwellis Inc
$0.77
+0.74%
HEALTHCARE · Cap: $2.48M
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 72155% more annual revenue ($6.51B vs $9.01M). EW leads profitability with a 15.4% profit margin vs -125.6%. EW earns a higher WallStSmart Score of 55/100 (C).
EW
Buy55
out of 100
Grade: C
NUWE
Avoid35
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+68.9%
Fair Value
$254.99
Current Price
$84.37
$170.62 discount
Margin of Safety
+90.0%
Fair Value
$22.04
Current Price
$0.77
$21.27 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Strong operational efficiency at 29.8%
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 25.4%
Smaller company, higher risk/reward
Weak financial health signals
ROE of -657.5% — below average capital efficiency
Earnings declined 99.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Debt/Equity, Altman Z-Score, Operating Margin. Profitability is solid with margins at 15.4% and operating margin at 29.8%. Revenue growth of 13.6% demonstrates continued momentum.
Bull Case : NUWE
The strongest argument for NUWE centers on Debt/Equity. Revenue growth of 14.1% demonstrates continued momentum.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 51.6x leaves little room for execution misses.
Bear Case : NUWE
The primary concerns for NUWE are Market Cap, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
EW profiles as a mature stock while NUWE is a turnaround play — different risk/reward profiles.
EW carries more volatility with a beta of 0.85 — expect wider price swings.
NUWE is growing revenue faster at 14.1% — sustainability is the question.
EW generates stronger free cash flow (585M), providing more financial flexibility.
Bottom Line
EW scores higher overall (55/100 vs 35/100), backed by strong 15.4% margins and 13.6% revenue growth. NUWE offers better value entry with a 90.0% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Nuwellis Inc
HEALTHCARE · MEDICAL DEVICES · USA
Nuwellis, Inc., a medical device company, focuses on the development, manufacture and marketing of medical devices used in ultrafiltration therapy. The company is headquartered in Eden Prairie, Minnesota.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?